Lachance Kim, White Michel, de Denus Simon
Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada.
Research Centre, Montreal Heart Institute, Montreal, QC, Canada.
Ann Transplant. 2015 Sep 29;20:576-87. doi: 10.12659/AOT.893788.
Although previous publications have discussed kidney disease in nonrenal solid-organ transplantation, none has reviewed thoroughly the potential predictors of long-term renal impairment in cardiac recipients. Thus, the purpose of this review article is to summarize the current state of knowledge on risk factors of chronic renal insufficiency in heart transplant patients. An English language Medline literature search (1946-April 2014) was conducted using the search terms renal insufficiency, kidney failure, kidney diseases, nephrotoxi$ ($ for truncation), creatinine, glomerular filtration rate, heart transplantation and organ transplantation. Additional references were identified from a review of literature citations. A total of 74 articles discussing key risk factors were included in the manuscript. The existing literature reveals that several recipient characteristics (age, female sex, pretransplant/early post-transplant kidney impairment, diabetes, and hypertension) increase the risk of renal insufficiency after transplantation. Current data also indicate that, while cyclosporine and tacrolimus are most likely major determinants of post-transplant kidney failure, the effects of calcineurin inhibitor doses and concentrations remain unclear. A small number of studies suggest that tacrolimus could possibly induce less nephrotoxicity than cyclosporine, but meta-analyses of randomized controlled trials show the opposite with comparable incidences of dialysis after cardiac transplantation. Finally, the role of genetic variations has only been explored to a limited extent in heart transplant patients. This growing body of evidence should ultimately lead to a better risk prediction regarding chronic renal insufficiency following cardiac transplantation and a more personalized tailoring of immunosuppressive regimens.
尽管先前的出版物已经讨论了非肾实体器官移植中的肾脏疾病,但尚无一篇全面综述心脏移植受者长期肾功能损害的潜在预测因素。因此,这篇综述文章的目的是总结心脏移植患者慢性肾功能不全危险因素的当前知识状态。我们使用搜索词肾功能不全、肾衰竭、肾脏疾病、肾毒素($表示截断)、肌酐、肾小球滤过率、心脏移植和器官移植,进行了英文医学文献数据库(1946年 - 2014年4月)的检索。通过对文献引用的回顾确定了其他参考文献。共有74篇讨论关键危险因素的文章被纳入本文。
现有文献表明,一些受者特征(年龄、女性、移植前/移植后早期肾功能损害、糖尿病和高血压)会增加移植后肾功能不全的风险。目前的数据还表明,虽然环孢素和他克莫司很可能是移植后肾衰竭的主要决定因素,但钙调神经磷酸酶抑制剂的剂量和浓度的影响仍不清楚。少数研究表明,他克莫司可能比环孢素诱导的肾毒性更小,但心脏移植后随机对照试验的荟萃分析显示结果相反,透析发生率相当。最后,基因变异在心脏移植患者中的作用仅在有限程度上得到探索。这些越来越多的证据最终应能更好地预测心脏移植后慢性肾功能不全的风险,并更个性化地调整免疫抑制方案。